Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced Monday it has acquired Knoxville-based Cerveau Technologies, Inc. (“Cerveau”). Cerveau’s asset is MK-6240, a second-generation F 18-labeled positron emission tomography (“PET”) imaging agent that targets Tau tangles in Alzheimer’s disease.
Read the full article: Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s Disease //
Source: https://www.globenewswire.com/news-release/2023/02/06/2602495/0/en/Lantheus-Announces-Acquisition-of-Cerveau-Technologies-Inc-Expanding-Imaging-Pipeline-into-Alzheimer-s-Disease.html